Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO1 | P00395 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15662249 | 0.78 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL15662250 | 0.78 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL17014183 | 0.78 | KDM4E (0.31) | — | |
| SCHEMBL17014184 | 0.74 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL18306897 | 0.74 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL15294847 | 0.74 | ATM (0.34) | — | |
| SCHEMBL15294850 | 0.70 | ALDH1A1 (0.34) | — | |
| SCHEMBL15294849 | 0.70 | — | — | |
| SCHEMBL1693716 | 0.67 | MT-CO1 (0.36) | MT-CO1MT-CO2EDNRAOPRM1HTR2B | |
| SCHEMBL31607681 | 0.67 | MT-CO1 (0.36) | MT-CO1MT-CO2EDNRAOPRM1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328124-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150232483-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232483-A1 | BACE INHIBITORS | BACE1, BACE2, APP | MT-CO1 1583/4885MT-CO2 2632/4885EDNRA 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.